Cephalon, Inc., (CEPH) announced that the company's executive vice president of worldwide pharmaceutical operations, Robert Roche, Jr., will resign his position with the company, effective February 5, to pursue other longstanding interests.
Since 1995, Roche has led the worldwide commercial organization which now has more than 30 products. He was promoted to senior vice president, worldwide pharmaceutical operations, in 2000, and named an executive vice president in 2005.
Before joining Cephalon, Roche served as director and vice president, worldwide strategic product development, for SmithKline Beecham's central nervous system and gastrointestinal products business.
The company said that during his tenure, Roche established and grew the Cephalon sales and marketing organization into a global business that exceeded $2 billion in annual sales revenue.
The company will announce plans for its leadership and the commercial organization in the near future.
In addition, the company said that the global commercial leadership team, Alain Aragues, president of Cephalon Europe, Paul Li, senior vice president of international pharmaceutical operations, and Robert Repella, senior vice president of U.S. pharmaceutical operations, will continue to lead their respective organizations.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.